Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group Journal Article

  


Authors: Ng, A. K.; Yahalom, J.; Goda, J. S.; Constine, L. S.; Pinnix, C. C.; Kelsey, C. R.; Hoppe, B.; Oguchi, M.; Suh, C. O.; Wirth, A.; Qi, S.; Davies, A.; Moskowitz, C. H.; Laskar, S.; Li, Y.; Mauch, P. M.; Specht, L.; Illidge, T.
Article Title: Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group
Abstract: Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios. © 2017 Elsevier Inc.
Keywords: chemotherapy; radiotherapy; stem cell transplantation; oncology; radiation oncology; stem cells; disease control; dose fractionation; diffuse large b-cell lymphoma; clinical outcome; curative intent; treatment volumes; optimal timing
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 100
Issue: 3
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2018-03-01
Start Page: 652
End Page: 669
Language: English
DOI: 10.1016/j.ijrobp.2017.12.005
PROVIDER: scopus
PUBMED: 29413279
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044650018&doi=10.1016%2fj.ijrobp.2017.12.005&partnerID=40&md5=4a7f609be8363aa50739cc663b75a1d9
Notes: Review -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    625 Yahalom
  2. Craig Moskowitz
    407 Moskowitz
Related MSK Work